drugset
drugset / Trial / NCT03455972

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

NCT03455972 ↗

Phase 1/2 Active not recruiting 43 enrolled The First Affiliated Hospital of Soochow University
NaSingle-groupOpen-labelTreatment

Summary

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after auto-HSCT.To test the safety and efficacy of giving targeting CD19 and BCMA T cells in treating high risk multiple myeloma followed with auto-HSCT.

Timeline

Start
2018-02-20
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-CD19-CAR Cell therapy 1e+07 cells/kg Intravenous
Subject anti-BCMA CAR Cell therapy 5e+07 cells/kg Intravenous

Indications

No indication recorded.